GLG News by Oncologists (US)

Rituxan failed to improve various parameters and targets in a rather comprehensive study of patients with Lupus.

This study is notable for several reasons: (1) it looked at 2 dose of BIBF 1120 and found essentially no difference in tumor control between the higher and lower dose regimens; (2) it included only patients who had previously received chemotherapy, and therefore, by definition, were less likely to have...

ZymoGenetic appears to have a biologic that will expedite lymphocytes apoptosis (destruction) when combined with Fludara and Rituxan- 2 standard agents in this rather common & occasional refractory condition.

This non erythropoietin (Epo) product will raise hemoglobin levels and decrease the need for transfusions.

While only a Phase II study, it suggest that Oral PBI-14 may be of significant help to cancer patients who suffer from anemia caused by their chemotherapy. http://www.pipelinereview.com/content/view/19152/109/ This is especially notable given the recent saftey concerns about and decline in use...

Doubles survival BUT "comparator" arm is best supportive care. See http://investor.poniard.com/ReleaseDetail.cfm?ReleaseID=306218

This is a better target than IL-5.  But some of the issues are the same.

The battle between hype and hope continues.

To call these result positive is to be very optimistic.

Another anti-TNF for Crohns Disease.  How will it stack up against the competition?